rucaparib
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
In the March 2019 issue of Pharmacoeconomics, Guy et al. evaluated the cost effectiveness of niraparib compared with routine…
In an interim analysis, the targeted PARP inhibitor rucaparib showed encouraging signs of disease control when used as a…
Für Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom stehen nach Versagen einer Androgenrezeptor-gerichteten…
Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer…
Introduction: Although recent studies employing 177 Lu-PSMA beta emitting targeted radiotherapy (TRT) have demonstrated efficacy…
High LOH is associated with response to the PARP inhibitor rucaparib in BRCA wild-type ovarian cancer.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA…
The present invention discloses 8 fluorine 2 { 4 [(methylamino) methyl] phenyl } 1,3,4,5 tetrahydrochysene 6H azepines comprising…
Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA singlestrand breaks. We recently…
Poly (ADP-ribose) polymerase (PARP) inhibitors are an emerging class of potential anti-cancer therapeutics currently being…